Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV Q1 2026 earnings

Reported April 30, 2026 · Before market open

Revenue$317.0MBeat by $44.2M
EPS$0.96Beat by $0.32
Revenue estimate$272.8M
EPS estimate$0.64

Next report

Aug 4, 2026 (In 5 days)
Revenue estimate$307.6M
EPS estimate$0.92

Financials

Q1 2026

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation & ratios

Valuation

as of 07/29/26
See full
Market cap$4.85B+125%
Enterprise value$5.18B+157%
P/E19.3×-0.7×
P/S3.8×+1.9×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Current ratio0.9×0.0×

Segments

By product

See full
SUBLOCADE$232.0M+31.8%
Sublingual & other$50.0M-7.4%
PERSERIS$5.0M+25.0%

By segment

See full
Reportable Segment$317.0M+19.2%

By geography

See full
Rest of World$45.0M+2.3%

Versus estimates

Revenue

Q1 2026$317.0MBeat by $44.2M
Q4 2025$358.0MBeat by $52.4MQ3 2025$314.0MBeat by $7.8MQ2 2025$302.0MBeat by $46.8MQ1 2025$266.0MBeat by $23.7MQ4 2024$299.0MBeat by $58.9M

Diluted EPS

Q1 2026$0.96Beat by $0.32
Q4 2025$0.82Beat by $0.17Q3 2025$0.72Beat by $0.34Q2 2025$0.51Beat by $0.25Q1 2025$0.41Beat by $0.19Q4 2024$0.32In line

Ask the moment Indivior Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Indivior Pharmaceuticals, Inc. report Q1 2026 earnings?
Indivior Pharmaceuticals, Inc. (INDV) reported Q1 2026 earnings on April 30, 2026 before market open.
What were Indivior Pharmaceuticals, Inc. 's Q1 2026 revenue and EPS?
Indivior Pharmaceuticals, Inc. reported revenue of $317.0M and eps of $0.96 for Q1 2026.
Did Indivior Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $272.8M by $44.2M. EPS beat the consensus estimate of $0.64 by $0.32.
How did Indivior Pharmaceuticals, Inc. 's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 19.2% from $266.0M a year earlier and eps grew 134.1% from $0.41.
Where can I find Indivior Pharmaceuticals, Inc. 's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-193925) and the 10-Q periodic report (0001628280-26-028850) directly on SEC EDGAR. The filing index links above go to sec.gov.